Factual Lead
Vantis Vascular announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for a new 6 French (6F) model of its CrossFAST Integrated Microcatheter Advanced Delivery System. The regulatory approval, designated under K262817, was granted on September 18, 2026. This milestone marks an expansion for the privately held medical technology company, which was founded by physicians and is based in San Jose, California. The newly cleared 6F CrossFAST model is scheduled for commercial availability in November, joining the existing 5.5F model that has been available in the United States since January 2025.
What Changed
The introduction of the 6F model brings distinct design modifications to the CrossFAST platform. According to Vantis Vascular, the new 6F version features a larger lumen designed to accommodate a broader range of interventional devices, alongside a shorter distal tip built specifically for complex percutaneous coronary intervention (PCI) procedures.
While the baseline CrossFAST system continues to utilize DuoPRO Interlocking Technology—which couples an inner monorail microcatheter with an outer delivery catheter to allow the entire system to advance as a single unit—the 6F model scales up the internal capacity of the device. This physical adjustment allows physicians to pass advanced diagnostic and therapeutic tools through the catheter system that previously required separate, non-integrated delivery steps or alternative pathways.
Technical and Business Explanation
CrossFAST is intended to be used in conjunction with guide catheters to access discrete regions of the coronary and peripheral vasculature, facilitating the placement of interventional devices. The core mechanics rely on DuoPRO Interlocking Technology. By locking the inner monorail microcatheter and the outer delivery catheter together, the system functions as one cohesive unit during advancement through difficult vascular anatomy.
The business and clinical significance of the 6F variant lies in its expanded compatibility. Vantis Vascular notes that the larger lumen accommodates interventional technologies routinely used in complex PCI, including intravascular ultrasound (IVUS) and intravascular lithotripsy (IVL). Clinical perspective highlights the growing importance of these tools. IVUS is critical in complex PCI cases, and its utilization has continued to expand over the years. By accommodating IVUS and other interventional technologies within the larger lumen, the 6F CrossFAST model allows physicians to deploy the platform in a wider variety of complex cases.
Sector Impact and Implications
For interventional cardiologists, the availability of a larger lumen integrated delivery system addresses specific procedural challenges encountered in calcified or highly tortuous coronary anatomy. The integration of devices like IVUS and IVL directly through the microcatheter delivery system can streamline workflow during demanding operations.
Industry observers note that medical device innovations focusing on procedural efficiency and device versatility often see rapid adoption among specialists performing complex interventions. Vantis Vascular’s physician-founded roots have guided the platform’s development toward addressing real-world catheter handling and deliverability hurdles. The 6F model represents an important expansion of technology designed around the needs of interventional cardiologists, widening the versatility of the CrossFAST platform while maintaining the integrated design and deliverability physicians expect.
Limitations and Regulatory Boundaries
As with all medical devices governed by FDA 510(k) clearances, the 6F CrossFAST model is cleared for specific intended uses—namely, to be used in conjunction with guide catheters to access discrete regions of the coronary and/or peripheral vasculature and facilitate placement of interventional devices. The device’s utility is bounded by these cleared indications, and its commercial deployment remains subject to standard medical device distribution timelines, with commercial availability scheduled for November 2026.
What to Watch Next
With commercial availability slated for November alongside the existing 5.5F model, market watchers will track the adoption rates of the 6F CrossFAST among hospital cardiac catheterization laboratories. Future developments may include further clinical feedback from complex PCI procedures utilizing the larger lumen configuration with IVUS and IVL devices, as well as potential continued expansion of the CrossFAST product family by Vantis Vascular.